Intermittent Intravenous Insulin Therapy — CPB 0742 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, reaffirmed and modified CPB 0742 on November 27, 2025, classifying all forms of intermittent intravenous insulin therapy as experimental and unproven — meaning claims for G9147, CPT codes 82947–84540, and related insulin HCPCS codes will be denied across every indication. Here's what billing teams need to do.

This Aetna intermittent intravenous insulin therapy coverage policy covers a treatment that goes by many names — pulsatile IV insulin therapy, physiologic insulin re-sensitization (PIR) infusions, hepatic activation therapy, metabolic activation therapy, and Trina Health artificial pancreas treatment. None of them get coverage. The effective date is November 27, 2025, and the denial language in CPB 0742 Aetna system applies to diabetes management and every other indication listed in the policy. If your practice or infusion center bills for any of these services to Aetna members, this affects your reimbursement immediately.

Quick-Reference Table

Aetna Intermittent Intravenous Insulin Therapy Coverage Criteria and Medical Necessity Requirements 2025

The short version: there are no coverage criteria that will get you paid for this service under Aetna's coverage policy. Aetna does not consider intermittent intravenous insulin therapy medically necessary for any indication. That includes diabetes mellitus management — which is the primary clinical use case — and extends to arthritis, cancer, infectious diseases, and any other condition.

Medical necessity is a non-starter here. Aetna's position is that the clinical effectiveness of this treatment has not been established, full stop. This isn't a situation where you can build a stronger prior authorization package or gather more documentation to flip a denial. The policy explicitly designates the entire category as experimental, investigational, or unproven.

Prior authorization won't help you either. When a payer classifies a service as experimental, prior auth isn't a pathway to reimbursement — it's a dead end. Don't let a practice manager submit a prior authorization request thinking it will clear the claim. It won't. The denial will come at the coverage policy level, not the prior auth review level.

One critical exception: the policy does not apply to insulin infusions used for diabetic ketoacidosis (DKA) or hyperosmolar coma. If your team bills for emergent insulin infusions in those specific contexts, CPB 0742 does not govern those claims. Know the difference between emergency metabolic management and the elective intermittent IV insulin protocols this policy is designed to block.

Aetna Intermittent Intravenous Insulin Therapy Exclusions and Non-Covered Indications

This policy has three distinct exclusion categories. Each one is worth understanding separately, because the billing exposure differs across them.

Intermittent IV insulin therapy itself — under any of its aliases — is non-covered for all indications. That includes CPT G9147 (Outpatient Intravenous Insulin Treatment, whether pulsatile or continuous, by any means). If you see "Trina Health," "pulse insulin therapy," or "PIR infusions" on a patient's treatment plan, G9147 will deny.

Insulin potentiation therapy (IPT) is separately called out as experimental. IPT is sometimes marketed as a cancer adjunct — particularly for breast and prostate cancer — or for arthritis and infectious diseases. The ICD-10 ranges in this policy cover neoplasms (C00.0–D49.9), arthropathies (M00.00–M25.9), and infections (A00.0–B99.9). Claims linking any of those diagnoses to intermittent IV insulin administration will deny.

Diagnostic labs performed in this context are also non-covered. This is the part billing teams miss most often. CPT codes 82947 (glucose, quantitative blood), 82948 (glucose, reagent strip), 82950 (post glucose dose), 84132 (potassium, serum/plasma/whole blood), 84133 (potassium, urine), and 84540 (urea nitrogen, urine) are not covered when performed as part of an intermittent IV insulin therapy protocol. Aetna's position is that these labs have no established clinical value in this context. Even if those labs would be covered in another clinical setting, their connection to this protocol is enough to trigger a claim denial.

This last point has real financial exposure. A billing team that doesn't flag the clinical context of those glucose and potassium labs can submit what looks like a routine lab claim — and still get denied. Context kills the claim, not just the procedure code.

Coverage Indications at a Glance

Aetna Intermittent Intravenous Insulin Therapy Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Intermittent Intravenous Insulin Therapy Under CPB 0742

Not Covered CPT Codes — Denied When Performed in the Context of This Protocol

Not Covered HCPCS Codes

Related HCPCS Insulin Codes (Flagged by Policy)

These codes are listed in CPB 0742 as related codes. They are not independently blocked, but claims that pair them with intermittent IV insulin therapy protocols or IPT will deny.

Key ICD-10-CM Diagnosis Codes Referenced in CPB 0742